No Data
No Data
No Data
No Data
No Data
Reunion Neuroscience On The Brink Of Going Private With Final Court Approval
Clinical-stage psychedelics company Reunion Neuroscience (NASDAQ:REUN) is about to close on its take-private transaction with MPM BioImpact affiliates, as shareholders voted for a special resolution a
BenzingaJul 18, 2023 05:04
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
World's Largest Psychedelics Conference Boasts 12K Attendees The Multidisciplinary Association for Psychedelic Studies (MAPS) sponsored a Psychedelic Science conference in Denver last week, which gath
BenzingaJul 4, 2023 22:21
Reunion Neuroscience's Q4 And Full Year 2023 Financial Results, To Close Take-Private Deal In Q3
Clinical-stage psychedelics firm Reunion Neuroscience Inc. (NASDAQ:REUN) reported fiscal results for the fourth quarter and year ended March 31 plus corporate updates. Here's a breakdown of the report
BenzingaJun 30, 2023 01:22
Ketamine News: PharmaTher Begins FDA Filing For KETARX Application, Stella Acquires Field Trip Assets
Specialty biotech company PharmaTher Holdings Ltd. (OTCQB:PHRRF) has filed a pre-submission facility correspondence in advance of its Abbreviated New Drug Application (ANDA) for its novel racemic keta
BenzingaJun 28, 2023 06:05
Can Field Trip Health & Wellness Re-Emerge From Creditor Protection? What The CCAA Data Shows
Potentially, a significant business casualty has befallen the psychedelic sector. Early industry leader, Field Trip Health & Wellness (OTC:FTHWF), has announced that it has obtained an Order for credi
BenzingaMar 28, 2023 01:05
Field Trip Health & Wellness Ltd. Brief: Says Has Obtained CCAA Protection
02:14 PM EDT, 03/22/2023 (MT Newswires) -- Field Trip Health & Wellness Ltd. Brief: Says Has Obtained CCAA Protection
MT NewswiresMar 23, 2023 02:16
No Data
No Data